Guardian Pharmacy Services, Inc. (GRDN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Guardian Pharmacy Services, Inc. (GRDN) Healthcare & Pipeline Overview

Guardian Pharmacy Services provides technology-enabled pharmacy solutions for long-term care facilities in the U.S., specializing in lower acuity settings like assisted living and behavioral health facilities. Their services include clinical support, drug dispensing, and administration, enhanced by their Guardian Compass data analytics platform, positioning them as a key player in the medical distribution sector.

What Is the Investment Thesis for GRDN?

Guardian Pharmacy Services presents a notable research candidate within the growing long-term care market. The company's focus on lower acuity LTCFs, a segment often underserved by larger pharmacy providers, allows for specialized service offerings and stronger customer relationships. With a P/E ratio of 41.74 and a profit margin of 3.6%, there is room for improvement in profitability through operational efficiencies and strategic pricing. The company's beta of 0.47 suggests lower volatility compared to the overall market, making it a potentially stable investment. Key growth catalysts include expanding their Guardian Compass platform to offer more advanced analytics and integrating additional clinical services to enhance patient care. The increasing demand for LTCF services, driven by the aging population, further supports the investment thesis. Ultimately, Guardian Pharmacy Services' technology-enabled solutions and focus on a specific market segment position it for sustained growth and value creation.

Based on FMP financials and quantitative analysis

GRDN Key Highlights

Market Cap of $2.76B indicates a significant presence in the healthcare sector.

• P/E Ratio of 41.74 suggests investors are paying a premium for its earnings, reflecting growth expectations.
• Profit Margin of 3.6% shows room for improvement compared to industry leaders.
• Gross Margin of 20.2% demonstrates the profitability of its core pharmacy services.
• Beta of 0.47 indicates lower volatility compared to the broader market, suggesting a relatively stable investment.

Who Are GRDN's Competitors?

GRDN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GRDN's Key Strengths?

Specialized expertise in serving lower acuity LTCFs.

• Technology-enabled solutions for efficient pharmacy operations.
• Strong relationships with LTCF providers.
• Comprehensive suite of clinical and administrative services.

What Are GRDN's Weaknesses?

Relatively low profit margin compared to industry leaders.

• Dependence on reimbursement rates and regulatory environment.
• Limited brand recognition outside of the LTCF market.
• Potential for increased competition from larger pharmacy chains.

What Could Drive GRDN Stock Higher?

Expansion of Guardian Compass platform to include advanced analytics and predictive modeling.

• Increasing demand for LTCF services due to the aging population.
• Strategic partnerships with LTCF providers to integrate pharmacy services into care delivery models.

What Are the Key Risks for GRDN?

Rich valuation — a P/E of 41.74 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $419.3M recently.
• Changes in government regulations and reimbursement policies impacting pharmacy revenue.
• Increased competition from larger pharmacy chains entering the LTCF market.
• Economic downturn affecting LTCF occupancy rates and ability to pay for services.
• Potential for medication errors and associated liability claims.

What Are the Growth Opportunities for GRDN?

• Expansion into New Geographic Markets: Guardian Pharmacy Services has the opportunity to expand its geographic footprint by targeting underserved regions with a high concentration of LTCFs. This expansion could involve establishing new pharmacy locations or acquiring existing regional pharmacy providers. The market for LTCF pharmacy services is estimated to be worth billions of dollars annually, and by strategically expanding into new markets, Guardian can capture a larger share of this growing market. Timeline: Ongoing.
• Enhancement of Technology Platform: Investing in and enhancing the Guardian Compass platform can provide significant growth opportunities. By incorporating advanced analytics, predictive modeling, and real-time monitoring capabilities, Guardian can offer LTCFs more actionable insights to improve patient care, reduce costs, and optimize medication management. This enhanced technology platform can also attract new customers and differentiate Guardian from its competitors. Timeline: Ongoing.
• Development of Specialized Clinical Programs: Creating and implementing specialized clinical programs tailored to specific patient populations within LTCFs can drive growth and improve patient outcomes. These programs could focus on areas such as medication adherence, chronic disease management, and pain management. By offering these specialized programs, Guardian can demonstrate its value to LTCFs and attract new customers seeking comprehensive pharmacy solutions. Timeline: Ongoing.
• Strategic Partnerships with LTCF Providers: Forming strategic partnerships with LTCF providers can create mutually beneficial growth opportunities. These partnerships could involve integrating Guardian's pharmacy services into the LTCF's care delivery model, collaborating on research initiatives, and developing joint marketing programs. By aligning its interests with those of LTCF providers, Guardian can strengthen its customer relationships and drive long-term growth. Timeline: Ongoing.
• Acquisition of Smaller Regional Pharmacies: Guardian Pharmacy Services can pursue a growth strategy through the acquisition of smaller regional pharmacies that serve the LTCF market. These acquisitions can provide Guardian with access to new markets, customers, and talent. By integrating these acquired pharmacies into its existing network, Guardian can achieve economies of scale and improve its overall operational efficiency. Timeline: Ongoing.

What Are GRDN's Competitive Advantages?

• Specialized focus on lower acuity LTCFs allows for tailored service offerings.
• Technology-enabled solutions, such as Guardian Compass, provide a competitive advantage.
• Strong relationships with LTCF providers create customer loyalty.
• Scalable business model allows for efficient expansion into new markets.

What Does GRDN Do?

Founded in 2003 and headquartered in Atlanta, Georgia, Guardian Pharmacy Services, Inc. has established itself as a leading provider of pharmacy services tailored to the long-term care facility (LTCF) market. The company recognized a need for specialized pharmacy solutions that cater to the unique requirements of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Unlike traditional pharmacies, Guardian Pharmacy Services focuses on delivering individualized clinical, drug dispensing, and administration capabilities designed to improve patient outcomes and streamline operations for LTCFs. Their comprehensive suite of services includes medication therapy management, adherence programs, and specialized packaging to ensure accurate and timely medication delivery. A key differentiator is their technology-driven approach, exemplified by Guardian Compass, a proprietary data analytics platform that provides local pharmacies with real-time insights to optimize business operations, track performance, and enhance patient care. Furthermore, the GuardianShield Programs offer LTCFs additional support in areas such as regulatory compliance, risk management, and staff training. With approximately 3,400 employees, Guardian Pharmacy Services operates a network of pharmacies across the United States, serving a diverse range of LTCFs and solidifying its position as a trusted partner in the long-term care industry.

What Products and Services Does GRDN Offer?

• Provide technology-enabled pharmacy services to long-term care facilities (LTCFs).
• Offer individualized clinical services to residents in lower acuity LTCFs.
• Dispense and administer medications to residents in LTCFs.
• Provide data-driven insights through their Guardian Compass platform.
• Offer GuardianShield Programs for LTCFs, focusing on regulatory compliance and risk management.
• Support assisted living facilities, behavioral health facilities, and group homes with specialized pharmacy solutions.

How Does GRDN Make Money?

• Generate revenue through dispensing prescription medications to residents in LTCFs.
• Offer clinical services, such as medication therapy management and adherence programs, for additional fees.
• Provide technology solutions, such as the Guardian Compass platform, on a subscription basis.
• Partner with LTCFs to provide comprehensive pharmacy services and share in cost savings.

What Industry Does GRDN Operate In?

Guardian Pharmacy Services operates within the medical distribution industry, specifically focusing on the long-term care pharmacy market. This market is experiencing growth due to the aging population and increasing demand for LTCF services. The competitive landscape includes both large national pharmacy chains and smaller regional providers. Guardian differentiates itself through its technology-enabled solutions, specialized services for lower acuity LTCFs, and data-driven approach to optimizing pharmacy operations. The industry is also subject to regulatory changes and reimbursement pressures, requiring companies to adapt and innovate to maintain profitability.

Who Are GRDN's Key Customers?

• Assisted living facilities (ALFs).
• Behavioral health facilities.
• Group homes.
• Other lower acuity long-term care facilities.

Over the past six months, Guardian Pharmacy Services, Inc. insiders filed 33 SEC Form 4 transactions — 20 sales and 13 purchases. On net that is roughly 14.1M shares disposed (about $419.3M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Guardian Pharmacy Services, Inc.

Revenue for Guardian Pharmacy Services, Inc. came in at $351.8M during Q2 FY2026, a 4.5% improvement versus the preceding quarter. The company recorded net income of $21.9M, with diluted EPS of $0.34. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, GRDN averaged $0.26 in diluted EPS.

GRDN Valuation & Market Position

With a $2.76B market cap, Guardian Pharmacy Services, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $40.00 to $49.00, with a consensus of $45.33. At the current price of $43.66, that implies approximately 4% upside potential. Relative to its peer group, GRDN's quantitative score of 96/100 is above the peer average of 50/100.

Return on equity for Guardian Pharmacy Services, Inc. stands at 27.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.4%, showing how much profit it generates from its asset base. GRDN trades at a trailing price-to-earnings ratio of 41.74, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.

Guardian Pharmacy Services, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.57 places it in the safe zone, indicating low near-term bankruptcy risk.

Guardian Pharmacy Services, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 133.2% below estimates on average.

Company Profile

Guardian Pharmacy Services, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Atlanta, US. The company is led by CEO Fred Burke. GRDN has traded publicly since 2024.

GRDN Financials

GRDN Latest News

GRDN Analyst Consensus

GRDN MoonshotScore

Latest Guardian Pharmacy Services, Inc. Analysis

What Investors Ask About Guardian Pharmacy Services, Inc. (GRDN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources